Experimental Basis for Immunotherapy of Metastases
Novel biological strategies have emerged in recent years for the treatment of cancer. These include transfer of hematopoietic stem cells for marrow reconstitution (BMT) after high-dose chemotherapy, transfer of activated tumor-reactive lymphocytes for adoptive cellular immunotherapy (ADI) of cancer and metastases, postoperative active specific immunization (ASI) with cancer vaccines, gene therapy, differentiation therapy, antisense therapy, immunotoxins or receptor-based therapies. Some biological treatments have already been established for certain forms of cancer, for instance interferon-α administration for Hairy cell leukemia, BCG (Bacillus Calmette Guérin) for superficial bladder carcinoma and allogeneic or autologous BMT for certain leukemic diseases. ADI was reported to have an overall response rate of about 25% in metastatic melanoma and renal cell carcinoma patients. For the vast majority of human cancer, however, such as carcinomas of lung, gastrointestinal tract, breast or prostate, no effective biological treatments have been found yet.
This report does not attempt to review the whole area of immunotherapy but focuses on progress from the author’s laboratory.
KeywordsLymphoma Leukemia Oncol Bacillus Interferon
Unable to display preview. Download preview PDF.
- 2.Roschenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber D,Aebersold P, Leitman S, Linehan WM, Seipp CA, White DE, Steinberg SM (1993) Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Nat Cancer Inst 85: 622–632CrossRefGoogle Scholar
- 4.Rocha M, Umansky V, Lee K, Hacker HJ, Benner A, Schirrmacher V (1997) Differences between graft-versus-leukemia (GvL) and graft-versus-host (GvH) reactivity. I. Interaction of donor immune T cells with tumor and/or host cells. Blood 6: 2189–2202Google Scholar
- 9.Rocha M, Kruger A, Van Rooij en N, Schirrmacher V, Umansky V (1995) Liver endothelial cells participate in T cell dependent host resistance to lymphoma metastasis by production f nitric oxide in vivo: Int J Cancer 63: 405–411Google Scholar
- 17.Schirrmacher V, von Hoegen P (1993) Importance of tumor cell membrane integrity and viability for CTL activation by cancer vaccines. Vaccine Research 2, No. 3: 183–196Google Scholar
- 20.Schirrmacher V, Griesbach A, Zangemeister U (994) GGG-Irradiated viable tumor cells as whole cell vaccines can stimulate in situ syngeneic anti-tumor CTL and DTH reactivity while tumor cell lysates elicit only DTH reactivity. Vaccine Research 3, No. 1: 31–48Google Scholar
- 21.Schlag P, Manasterski M, Gerneth Th, Hohen-berger P, Dueck M, Herfarth Ch, Liebrich W, Schirrmacher V (1972) Active specific immunotherapy NDV modified autologous tumor cells following liver metastases resection in colorectal cancer: first evaluation of clinical response of a phase II trial. Cancer Immunol Immunother 35: 325–330CrossRefGoogle Scholar
- 23.Ockert D, Schirrmacher V, Beck N, Stoelben E, Ahiert T, Flechtenmacher J, Hagmüller E, Nagel M, Saeger HD (1996) Newcastle disease virus in- fected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res 2: 21–28PubMedGoogle Scholar
- 24.Pomer S, Thile R, Daniel V, Wiemer R, Löhrke H, Schirrmacher V, Staehler G (1991) Sequential treatment of patients with advanced renal cell carcinoma with autologous tumor vaccine and subcutaneous administration of recombinant Interleukin-2 and Interferon-a-2b. World J Urol 9: 223–227CrossRefGoogle Scholar
- 28.Stoeck M, Marland-Noske C, Manasterski M, Zawatzky R, Horn S, Möbus V, Schlag P, Schirrmacher V (1993) In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumor cells. Cancer Immunol Immunother 37: 240–244PubMedCrossRefGoogle Scholar